Follow the SK바이오사이언스 share price and the full management transaction log of the company, a listed equity based in South Korea. Shares trade on KR KR, under the oversight of DART (FSS). Operating in the Technology sector, SK바이오사이언스 has published 68 insider filings. Market capitalisation: €1,526,188bn. The latest transaction was reported on 24 February 2026 (Purchase). Among the most active insiders: 김훈. All data is openly available.
68
Insider Decl.
0
Thresholds
·
53 ops.
Buy Volume
·
5 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate SK바이오사이언스 Strong Buy (bullish), based on 38 analysts. Average price target: ₩2,523,542.
2Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 7,386 of 25,837 companies
62.3
score / 100
Value
36
Quality
89
FCF yld1.4%
Earn yld2.4%
EV/EBITDA28.1x
ROE61%
Gross mgn60%
Net mgn44%
Debt/EBITDA0.4x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
